TEM · 交易机会 · Trading Opportunity
Q4营收约$3.67亿同比增长约83%、全年营收约$12.7亿、Insights数据授权增速约70%、净营收留存率约126%、总剩余合同价值突破约$11亿、现金约$7.6亿、2026年首次正调整后EBITDA指引、今日刚宣布与默克建立AI精准医疗合作——摩根士丹利目标价下调引发情绪压制、股价回落至约$52：Cathie Wood ARK昨日单日大举买入、机构多空对峙创造罕见价格错位，临床AI数据基础设施最深护城河的最清晰建仓窗口今天正式开启
Q4 revenue approximately $367 million up approximately 83% year-over-year, full-year revenue approximately $1.27 billion, Insights data licensing growth rate approximately 70%, net revenue retention rate approximately 126%, total remaining contract value breaking through approximately $1.1 billion, cash approximately $760 million, 2026 first positive adjusted EBITDA guidance, today just announced AI precision medicine cooperation with Merck — Morgan Stanley target price cut triggering sentiment suppression, share price falling back to approximately $52: Cathie Wood ARK making large single-day purchases yesterday, institutional bull-bear standoff creating rare price dislocation, the clearest position-building window for the deepest moat in clinical AI data infrastructure officially opens today.
2026年初，Tempus AI发布全年业绩。
In early 2026, Tempus AI released full-year results.
Q4营收同比增长约83%。全年营收同比增长约83%。Insights数据授权增速约70%。净营收留存率约126%——意思是现有客户每年自动贡献约26%的额外营收增长，不需要任何新客户。总剩余合同价值突破约$11亿。现金约$7.6亿。最重要的：管理层首次给出正EBITDA全年指引。
Q4 revenue up approximately 83% year-over-year. Full-year revenue up approximately 83% year-over-year. Insights data licensing growth rate approximately 70%. Net revenue retention rate approximately 126% — meaning existing customers automatically contribute approximately 26% additional revenue growth every year without any new customers needed. Total remaining contract value breaking through approximately $1.1 billion. Cash approximately $760 million. Most importantly: management provided positive EBITDA full-year guidance for the first time.
两家机构，同一时间，方向截然相反。
Two institutions, same time, diametrically opposite directions.
ARK的反应：财报后次日单日大举买入逾20万股。摩根士丹利的反应：目标价下调，引发情绪性抛售。
ARK's reaction: the day after earnings, large single-day purchase of more than 200,000 shares. Morgan Stanley's reaction: target price cut, triggering emotional selling.
今天的股价：约$52。
Today's share price: approximately $52.
这是一个机构多空对峙制造的价格错位。ARK押注的是Tempus数据资产的长期战略价值；摩根士丹利担忧的是营收增速从约83%放缓至指引约25%的短期保守判断。两者之间的对峙，正在约$52创造一个与基本面实际状态严重背离的折价窗口。
This is a price dislocation created by an institutional bull-bear standoff. ARK is betting on the long-term strategic value of Tempus's data assets; Morgan Stanley is concerned about the short-term conservative judgement of revenue growth slowing from approximately 83% to guidance of approximately 25%. The standoff between the two is creating a discount window at approximately $52 that seriously diverges from the actual fundamental state.
今天还有一件额外的确认信号：Tempus刚刚宣布与默克建立AI驱动精准医疗合作——在财报后仅一周内落地新的旗舰级制药合作，是Insights数据授权商业动能持续加速的最直接近期证明。
Today there is one additional confirmation signal: Tempus just announced AI-driven precision medicine cooperation with Merck — a new flagship-level pharmaceutical cooperation landing within just one week after earnings is the most direct near-term proof of continuously accelerating Insights data licensing business momentum.
ARK在买，默克在签约，股价在约$52——三件事同时发生，方向一致。下半部分，我们会拆解净营收留存率约126%背后的真实护城河逻辑、机构多空对峙的具体分析，以及完整的分阶段建仓价位区间、三个阶段的止盈目标，和触发重新评估持仓的具体条件。
ARK is buying, Merck is signing contracts, share price is at approximately $52 — three things happening simultaneously, all pointing in the same direction. In the second half, we will break down the real moat logic behind the approximately 126% net revenue retention rate, the specific analysis of the institutional bull-bear standoff, and the complete tiered entry price ranges, three-stage profit-taking targets, and the specific conditions that trigger re-evaluation of the position.
